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Abstract
Background: Management of the node-positive axilla after neoadjuvant chemotherapy is controversial. The aim of
this study is to predict the group of patients who may require a less invasive approach for axillary management.
One possible group are patients with pathological complete response of the primary after chemotherapy.
Results: A unicentral retrospective cohort study including all breast cancer patients with axillary node metastases at
presentation who received neoadjuvant chemotherapy resulting in pathological complete response. Pathological
complete response in the axillary lymph nodes was recorded. A correlation between the response in the primary
tumour and the lymph nodes was assessed. A subgroup analysis was conducted for different biological groups.
Complete response was seen in the axillary nodes in 80.5% of patients. Patients with lobular cancer were less likely
to show a similar response in the axilla as the primary tumour (p = 0.077). A higher incidence of axillary response
was observed in HER2-positive tumours (p = 0.082). All patients with grade 3 tumours achieved complete response
in the axilla (p = 0.094). Patients with negative or weak positive hormone receptor status had a significantly higher
rate of complete response in the axilla compared to strongly positive hormone receptor status (OR, 7.8; 95% CI, 1.7–
34.5; p = 0.007).
Conclusion: A less invasive axillary surgery may be safely recommended in selected group of node-positive
patients after neoadjuvant chemotherapy when the primary tumour shows complete response. This group may
include HER2-positive, ER-negative and grade 3 tumours. Less response is expected in ER-positive and lobular
carcinoma even with complete response in the primary.
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Background
Neoadjuvant chemotherapy (NACT) is a well-established
treatment modality in breast cancer [1].
Its role has expanded to include early-stage breast can-
cer in addition to the standard indications for inoperable
and locally advanced tumours [2].
Potential benefits include downstaging the primary
tumour to allow for more conservative surgical manage-
ment [3], testing and monitoring the response of new
drugs in vivo [4] and allowing additional time for genetic
tests (e.g., BRCA1/2) whose results can affect the surgi-
cal management [5].
Although previous randomized controlled studies
showed no difference in survival between neoadjuvant
and adjuvant chemotherapy [6, 7], it is now understood
that achieving a pathological complete response (pCR) is
a surrogate for a favourable prognosis and a better
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disease-free and survival outcome [8]. This pCR is
mostly seen in HER2-positive and triple-negative sub-
types [9].
Management of the axilla following NACT has always
been a topic for debate [10, 11]. Management of a clinic-
ally node-negative (N0) axilla with a sentinel node bi-
opsy at the time of surgical resection is widely
acceptable as a standard of care [12].
However, the management of a clinically node-positive
(N1+) axilla is more controversial [13]. Many studies
have tried to address this issue [14–16]. The ABS guide-
lines for management of the axilla after neoadjuvant
chemotherapy cautiously recommend a targeted axillary
dissection (TAD) approach [17] in selected clinical
situations.
Some authors tried to establish a relation between the
response of the primary tumour and the axillary lymph
nodes in initially node-positive patients [18, 19]. The
aim is to predict the group of patients who may require
a less invasive approach for axillary management after
NACT [18]. One possible group is the patients who de-
velop complete pathological response (pCR) in the pri-
mary tumour after NACT [18].
This is a retrospective cohort study of axillary lymph
node-positive breast cancer patients at presentation who
showed a pCR of the primary tumour after NACT.
The aim of the study was to establish a relationship
between the pCR in the primary tumour and the re-
sponse in the axillary lymph nodes. We looked at the
pathological changes in the axillary lymph nodes status
within the group of patients with pCR in the primary.
The study questioned whether a pCR in the primary
tumour implied a corresponding downstaging of the ax-
illary lymph nodes status.
Establishing this relationship aims to safely identify a
potential group of patients with axillary lymph node me-
tastases at presentation where the axillary surgical sta-
ging procedure required may be less invasive after
completion of NACT.
Methods
A retrospective cohort study including all breast cancer
patients with axillary lymph node metastases at presen-
tation who received neoadjuvant chemotherapy (NACT)
resulting in pathological complete response (pCR) be-
tween January 2013 and December 2017 at a high-
volume tertiary referral centre operating on 2000 breast
cancer patients per year. Approval of the Institutional
Review Board was obtained for the study.
Patients who presented with breast cancer involving
the axillary lymph nodes (N1+) and received NACT
leading to a pCR following that were included. Breast
cancer patients with negative axillary lymph nodes (N0)
were excluded. Other exclusion criteria were patients
with distant metastatic disease (M1+) at presentation
and patients with N1+ disease, who received NACT but
showed any response less than pCR following that.
All patients were diagnosed with the standard triple
assessment, with additional imaging (e.g., MRI) done
whenever required. Hormone receptor (HR) and HER2
status were identified in the core biopsy through immu-
nohistochemistry (IHC). HR receptors quick score was
calculated. HER2 was assessed using FISH when the
IHC was equivocal.
Based on the tumour biology features, patients were
classified into 4 groups: Luminal A (HR+, HER2−), lu-
minal B (HR+, HER2+), HER2 enriched (HR−, HER2+)
and triple negative (HR−, HER2−).
Axillary lymph node involvement at presentation was
established by ultrasound scan of the axilla with a cor-
tical thickness more than 3mm and loss of the fatty
hilum. At the time of this study, no biopsy was
performed.
Each case was discussed at the multidisciplinary team
(MDT) meeting.
NACT regimen consisted mainly of a combination of
anthracyclines and taxanes or FEC. All HER2-positive
patients received NACT and trastuzumab with the latter
continued after surgery.
After completion of NACT, patients underwent breast
imaging to assess the response and to guide the surgical
planning. Surgical options included mastectomy with or
without immediate reconstruction, and breast conserv-
ing surgery (BCS). All patients underwent axillary node
clearance.
Pathological complete response (pCR) of the primary
tumour was established as absence of invasive or in situ
cancer (Miller and Payne score of 5) [20]. pCR in the ax-
illa was diagnosed when no residual tumour was found
in the lymph nodes, including isolated tumour cells and
micrometastases.
pCR in the axillary lymph nodes was recorded and
correlated with the initial status at presentation. A cor-
relation between the response in the primary tumour
and the lymph nodes was assessed. A subgroup analysis
was conducted for different biological groups.
Statistical analysis was done using IBM SPSS® Statistics
version 22 (IBM® Corp., Armonk, NY, USA). Numerical
data were expressed as mean and standard deviation or
median and range as appropriate. Qualitative data were
expressed as frequency and percentage. Pearson’s Chi-
square test or Fisher’s exact test was used to examine
the relation between qualitative variables. For not nor-
mally distributed quantitative data, comparison between
the two groups (N0 and N+) was done using Mann-
Whitney test (non-parametric t test). Multivariate ana-
lysis was done using logistic regression forward method
for the significant factors affecting lymph node positivity
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postoperatively on univariate analysis. Odds ratio (OR)
with it 95% confidence interval (CI) were used for risk
estimation. All tests were two-tailed. A p value < 0.05
was considered significant.
Results
Three hundred sixty-seven (367) patients received
NACT at the study centre between January 2013 and
December 2017. Of those patients, 77 (20.9%) achieved
pCR in the breast and were included in the study.
pCR was seen in the axillary lymph nodes in 62
(80.5%) of this cohort of patients. In the remaining
19.5% (15 patients), pCR was not observed in the axilla.
Clinicopathological characteristics of the study cohort
are listed in Table 1.
The median age of patients was 47 years (range 22 to
75 years). The median tumour size before neoadjuvant
chemotherapy was 4 cm (range 1.2 to 11 cm). The distri-
bution of the nodal stage at presentation (before NACT)
ranged between N1 (53 patients, 68.8%), N2 (22 patients,
28.5%) and N3 (2 patients, 2.5%).
The most common clinical stage was IIIA (43%).
Ninety percent of the patients showed an invasive duct
carcinoma and 10% had a lobular cancer. The molecular
subtypes were HER2 enriched (31%), TNBC (29.8%), Lu-
minal A (23.3%) and Luminal B (15.5%).
NACT regimen consisted mainly of a combination of
anthracyclines and taxol (48%) and FEC regimen (42%).
Other less commonly used regimens included FAC (3%),
taxane + carboplatin (2%), gemzar + carboplatin (1%)
and taxanes + endoxan (1%)
Sixty-four patients underwent mastectomy (83%), with
5 of them having immediate reconstruction. All the pa-
tients in the study had axillary clearance, with a mean
number of 12 lymph nodes harvested.
Sixty-two patients (80.5%) had a pCR in the axilla
demonstrated in the final histological assessment. Age,
pre-chemotherapy size of the primary tumour and num-
ber of lymph nodes harvested in the axillary clearance
had no effect on the development of pCR in the axilla (p
= 0.918, p = 0.876, p = 0.806).
Patients with lobular cancer were less likely to show a
similar pCR in the axillary lymph nodes as the primary
tumour than those with invasive ductal carcinoma (p =
0.077).
On the contrary, a higher incidence of axillary lymph
nodes pCR was observed in HER2-positive tumours
compared to other biological types including HER2-
enriched and luminal B subtypes (p = 0.082).
All patients with grade 3 tumours achieved pCR in the
axilla, compared to 78.9% of those with grade 2 tumours
(p = 0.094).
For the statistical purpose of determining the effect of
hormone receptor positivity, we grouped patients with
negative and weak positive hormone receptors together,
compared to patients with intermediate and strong hor-
mone receptor positivity.
On multivariate logistic regression analysis, the inde-
pendent factor that significantly affected the lymph node
positivity postoperatively was the degree of hormone re-
ceptor positivity. Patients with negative or weak positive
hormone receptor status had a significantly higher rate
of pCR in the axillary lymph nodes compared to those
with intermediate or strong positive hormone receptor/
status (OR, 7.8; 95% CI, 1.7–34.5; p = 0.007).
Discussion
This study addresses the question of whether a complete
pathological response observed in the primary tumour
after NACT can predict a similar response in the axillary
lymph nodes and therefore allow for less invasive surgi-
cal approach for axillary staging.
The rate of pCR of the breast in our study was 21%,
which is in keeping with the 22% from the meta-analysis
by Cortazar and Geyer [8] and the 24% of the Dutch
multicentre trial [19].
Patients who achieved pCR in both the breast and ax-
illa comprised 16.9% of all patient population, which is
similar to results from Schipper et al.’s 17.5% [21] and
Fayanju et al.’s 19% [22] studies that included 20,000
patients.
In our study, pCR of the primary tumour was associ-
ated with change in the stage of the axillary lymph nodes
after NACT. Patients who had presented initially with
positive axillary lymph nodes and showed a pCR in the
primary tumour mostly showed similar response pattern
in the axilla after clearance.
Morgan et al. [23] showed similar results in their study
which included 83 patients with pathological axillary
lymph nodes who received NACT. Twenty-one patients
had pCR in the breast. Of those, 17 (80%) had also a
complete response in the axilla which is the same per-
centage as our study.
Another study by Tadros et al. [24] included the same
number of patients as our study yet had a higher rate of
pCR in both the breast and axilla (89.6%). This differ-
ence can be attributed to the fact that the study only in-
cluded HER2-positive and triple-negative subtypes. The
multicentre study by Samiei et al. [19] reports a 45% of
patients (245/544) achieving pCR in both breast and
axilla.
The pCR in the primary corresponded to a similar re-
sponse in the axillary lymph nodes in most of the study
cohort.
There seem to be a variation among different groups
of patients treated with NACT in terms of the expected
response in the axilla following pCR of the primary.
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The presence of pCR in both the breast and axilla
depended largely on the molecular subtype of the
tumour. The commonest subtype was HER2 enriched
(91.7%) followed by Luminal B (83.3%), triple-negative
breast cancer (78.2%) and finally Luminal A (66.7%).
These results are in concordance to large database study
by Barron et al. [18] that included 30,821 patients who
received NACT. Among the 3128 patients who achieved
pCR in both the breast and axilla, the most common
molecular subtypes were HER2 enriched (88.7%), Lu-
minal B (86.7%), TNBC (85.9%) and Luminal A (69.5%).
A similar good response was observed in grade 3 tu-
mours as well, which was also witnessed in the multicen-
tre study by Samiei et al. (p = 0.045) [19].
The response was inversely proportional to the degree
of HR positivity, with HR-positive tumours less likely to
show pCR in the axillary lymph nodes following
complete response in the primary. This same
Table 1 Clinicopathological characteristics
Total group N0 N1 p value
Number 77 62 15
Mean age 47.4 (22–75) 47.3 (22–75) 47 (34–71) 0.918
Tumour stage
Stage IIB
T2 N1 15 13 2
Stage IIIA
T2 N2 1 0 1
T3 N1 25 18 7
T3 N2 12 11 1
Total 38 29 9
Stage IIIB
T4a N1 13 11 2
T4a N2 9 8 1
Total 22 19 3
Stage IIIC
T1 N3 1 0 1
T3 N3 1 1 0
Total 2 1 1
Histological type
IDC 68 57 11 0.077
ILC 6 3 3
Others 3 2 1
Molecular subtype
Luminal A 18 12 6 0.232
Luminal B 12 10 2
Her2+ 24 22 2
TNBC 23 18 5
Mean tumour size 4.1 cm (1.2–11) 4.2 cm (2.5–11) 3.8 cm (1.2–7) 0.876
Mean number of LNs 12.8 12.9 12.4 0.806
Histological grade
Grade 2 57 45 12 0.094
Grade 3 11 11 0
Unknown 9 6 3
Surgery
MRM 64 54 10 0.058
CBS 13 8 5
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observation which was described in the meta-analysis by
Houssami et al. [25] and the pooled analysis by Cortazar
et al. [26].
Patients with lobular cancer were less likely to show
similar pattern.
There have been previous published literature aiming
at predicting patients with axillary pathological complete
response following NACT.
Schipper et al. [21] proposed a model that included
patient age, clinical tumour stage, histological subtype,
hormone receptor and HER2 status, as well as receiving
trastuzumab and taxanes. Their model had a specificity
of 43% and PPV of 65%.
Kim et al. [27] proposed a prognostic nomogram to
predict who achieve axillary pCR following NACT. The
nomogram items included patient age, initial clinical T
stage, clinical nodal stage, tumour grade, ER, HER2,
Ki67 expression, clinical tumour and nodal response and
regimen of NACT.
The factors included in that nomogram seem to cor-
relate to the factors that we have identified as influen-
cing the pCR in both breast and axilla.
To the best of our knowledge, this is one of the few
studies looking specifically at the group of patients who
showed pCR in the primary tumour to establish correl-
ation with the axillary response. This group is identified
as a potential group where axillary staging could be less
invasive. It is possible that this group of patients can be
offered a less invasive axillary staging procedure such as
sentinel node biopsy or target axillary dissection.
We recognize many limitations to our study. A main
limitation is the fact that the axillary lymph node posi-
tivity was established pre-chemotherapy with ultrasound
scan and without a biopsy. Although the signs of a ma-
lignant lymph node on ultrasound are highly reliable
[28], most centres depend on a core biopsy to establish
this diagnosis. At the time of studying this cohort at our
centre, the radiological diagnosis was considered ad-
equate to establish nodal involvement. It is now clear
that most centres require core biopsy to confirm axillary
nodes involvement.
Another main limitation is the lack of availability of
target axillary dissection approach (TAD) [29]. In our
centre, this approach has not been adopted yet. Selected
patients with low disease burden in the axillary lymph
nodes initially could have been offered this approach in
an attempt to spare them axillary clearance. However,
most of the patients included in this study had presented
with heavy nodal involvement initially (at least 3 patho-
logical lymph nodes) and therefore would not have been
suitable for TAD according to the current guidelines
[17] even if it were available.
Another limitation is the retrospective nature of the
study. This is compensated by the high-quality data
accurately obtained from pathological reports to
minimize a recall bias. The small number of patients in-
cluded in the study reflects the real-life percentage of
patients with initial nodal metastases who develop pCR
(13–23% [19, 22]) in the primary.
Based on the findings in our study, a less invasive axil-
lary staging approach may be safely recommended in a
selected group of node-positive patients after NACT
when the primary tumour shows pCR. This group may
include HER2-positive, HR-negative and grade 3 tu-
mours. Less response is expected to be observed in the
axillary lymph nodes in HR-positive and lobular carcin-
oma even with pCR in the primary tumour.
However, more body of evidence to support this hy-
pothesis is needed. A target axillary dissection (TAD)
approach may be considered in early small nodal disease
[29] but should be discussed carefully within the MDT.
Further studies are needed to attempt at selecting
groups of node-positive patients who can be safely of-
fered less invasive axillary staging surgery after NACT.
A selected group of patients among those who show
pCR in the primary tumour are one of the possible
groups.
Conclusion
A correlation between a pathological complete response
in the primary tumour and the axillary lymph nodes is
more likely to be seen in patients with grade 3, HER2-
positive or HR-negative tumours. In this group, a more
conservative approach to axillary surgery can be safely
adopted, sparing them a full axillary clearance.
This group can be identified at MDTs, therefore avoid-
ing axillary clearance in patients who show pathological
complete response after neoadjuvant chemotherapy who
were initially node positive.
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